| Author, year | Study design | Participants (n) | Therapeutic administered (n) | Safety outcomes |
| Adler 2022 | Retrospective observational study | 4 receiving therapeutic treatment | Brincidofovir (3), tecovirimat (1) | Serious adverse events, development of complications, mental health outcomes |
| Mbrenga 2022 | Open access programme | 14 | Tecovirimat (14) | Serious adverse events, mortality |
| O'Laughlin 2022 | Retrospective observational study | 340 with safety information | Tecovirimat (340) | Serious adverse events, mental health outcomes |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.